Alharbi Dalia, Nadreen Marah, Albaiji Ayidah, Al-Jaroudi Dania
Reproductive Endocrine and Infertility Medicine Department. Women's Specialized Hospital, King Fahad Medical City, Riyadh Second Health Cluster, Saudi Arabia.
Obstetrics and Gynecology Department. Women's Specialized Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.
JBRA Assist Reprod. 2025 Mar 12;29(1):110-116. doi: 10.5935/1518-0557.20240076.
To compare the clinical outcomes, including pregnancy rate, live birth rate, and miscarriage rate between vaginal progesterone Cyclogest suppository and Crinone vaginal progesterone gel as LPS in frozen-thawed embryo transfer in Intra-Cytoplasmic Sperm Injection (ICSI) cycles.
In this comparative retrospective chart review, 283 women who had frozen-thawed embryo transfer were assessed. The patients were divided into two groups based on the route of progesterone administration used as LPS. When the endometrial thickness reached ≥8mm, vaginal progesterone Cyclogest 400 mg/twice daily suppository was administered in one group; in another group, vaginal progesterone Crinone 8% 90 mg daily was administrated until a positive pregnancy test was confirmed. This was continued for 10-12 weeks after embryo transfer when fetal heart activity was detected by ultrasonography.
The patients' characteristics in the two groups were matched and there was no significant difference. The biochemical and clinical pregnancy, miscarriage, and live birth rates were similar-4.7% vs. 2.7%, p=0.464; 26.1% vs. 23.3%, p=0.638; 13.3% vs. 9.6%, p=0.410; 15.6% vs. 16.4%, p=0.872, respectively; there was no statistically significant difference between the vaginal progesterone Cyclogest group and the Crinone progesterone group.
Clinical pregnancy, biochemical pregnancy, miscarriage, and live birth rates were similar between both groups. Moreover, vaginal progesterone Cyclogest and Crinone 8% gel are equally effective in providing support during the luteal phase for both blastocysts and cleavage-stage embryos in CET.
比较阴道用黄体酮Cyclogest栓剂和Crinone阴道用黄体酮凝胶作为黄体支持药物，在卵胞浆内单精子注射（ICSI）周期冻融胚胎移植中的临床结局，包括妊娠率、活产率和流产率。
在这项比较性回顾性图表审查中，对283例行冻融胚胎移植的女性进行了评估。根据用作黄体支持的黄体酮给药途径将患者分为两组。当子宫内膜厚度达到≥8mm时，一组给予阴道用黄体酮Cyclogest 400mg/每日两次栓剂；另一组给予阴道用黄体酮Crinone 8% 90mg/每日一次，直至确认妊娠试验呈阳性。胚胎移植后，当超声检查检测到胎心活动时，持续用药10 - 12周。
两组患者的特征相匹配，无显著差异。生化妊娠和临床妊娠、流产及活产率相似，分别为4.7%对2.7%，p = 0.464；26.1%对23.3%，p = 0.638；13.3%对9.6%，p = 0.410；15.6%对16.4%，p = 0.872；阴道用黄体酮Cyclogest组和Crinone黄体酮组之间无统计学显著差异。
两组的临床妊娠、生化妊娠、流产及活产率相似。此外，阴道用黄体酮Cyclogest和Crinone 8%凝胶在为冻融胚胎移植中的囊胚和卵裂期胚胎黄体期提供支持方面同样有效。
